APM Aptorum Group Ltd

CIK 0001734005 8 ready 8-Ks latest September 4, 2026, 4:31 PM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline

Ready 8-Ks 8

Latest filing October 13, 2026, 4:00 PM ET

Top materiality 0.80

Event mix leadership ×2 · m_and_a ×2 · other_material ×1

Sentiment 1 pos · 2 neg · 5 neu

Executive change recent →

SHENANIGAN SCORE 2 / 7 see the board

Recent 8-K filings for APM

Highest-materiality recent filing

Niki BioSolutions posts H1 2026 net loss of $1.3M, flags going-concern doubt

August 21, 2026, 5:00 PM ET earnings materiality 0.80 negative item 9.01

H1 2026 net loss attributable to Niki was $1,326,004 vs $441,780 in H1 2025; EPS loss of $1.6.
Cash fell to $1,834,171 from $3,452,891 at Dec 31, 2025; operating cash outflow of $1,553,720.

Read filing →

September 4, 2026, 4:31 PM ET leadership materiality 0.60 neutral item 5.02 item 9.01

Niki BioSolutions names Ian Huen CEO/Chairman and Alidad Mireskandari President/COO

Ian Huen appointed CEO and Chairman effective Aug 1, 2026; 6-month initial term, HKD 210,000/month (~USD 26,800).
August 21, 2026, 5:17 PM ET M&A materiality 0.70 negative item 9.01

Niki BioSolutions closes DiamiR merger; acquired firm posts FY2026 net loss and going-concern doubt

Merger closed July 20, 2026; DiamiR Biosciences became a wholly-owned subsidiary of Niki BioSolutions (formerly Aptorum Group).
August 21, 2026, 5:00 PM ET earnings materiality 0.80 negative item 9.01

Niki BioSolutions posts H1 2026 net loss of $1.3M, flags going-concern doubt

H1 2026 net loss attributable to Niki was $1,326,004 vs $441,780 in H1 2025; EPS loss of $1.6.
July 20, 2026, 8:15 AM ET M&A materiality 0.75 neutral item 2.01 item 3.03 item 5.02 item 5.03 item 8.01 item 9.01

Aptorum completes merger with DiamiR, redomiciles as Niki BioSolutions, trades under NIKI

Merger closed July 20, 2026; Aptorum redomiciled to Delaware and renamed Niki BioSolutions, Inc.

Executive changes

Appointed

Thomas Freeburg

Chief Financial Officer

APM · Aptorum Group Ltd

Effective: 2026-09-01
Filed: October 13, 2026, 4:00 PM ET

On October 9, 2026, the Board of Directors (the “Board”) of Niki BioSolutions, Inc., a Delaware corporation (the “Company”), appointed Thomas Freeburg as the Chief Financial Officer, to serve at the discretion of the Board, for a period of two years, commencing as of September 1, 2026, unless terminated sooner by either party.

Materiality & sentiment trend

Max materiality 0.80 · Median 0.57 · Most common event leadership

1 positive 2 negative 5 neutral

source · APM on sec.gov